This article was originally published in The Gray Sheet
Executive SummaryPMA supplement covering use of TriPath's SurePath liquid-based cytology specimen collection medium for cervical cancer screening with Digene's Hybrid Capture 2 HPV DNA test would allow HPV testing directly from SurePath specimens. Formerly called CytoRich, SurePath preservation vials and density reagents were approved for use on the AutoCyte PREP system, now called PrepStain, via PMA supplement in May 2001. Digene announced the filing for the Hybrid Capture 2, currently approved as a follow-up to borderline Pap test results, April 16...
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.